{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:37:29Z","timestamp":1794947849781,"version":"4.9.1"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Sj\u00f6gren disease (SjD) constitutes a diagnostic and therapeutic challenge due to its clinical heterogeneity and complex pathophysiology. This review synthesizes recent advances in diagnostics, disease stratification, and targeted therapies, highlighting their potential to optimize patient care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Emerging diagnostic approaches include advanced salivary, lacrimal, and serum biomarkers, refinements of established diagnostic tools, role of specific autoantibodies, and AI-assisted histopathology, improving early detection and risk stratification, particularly for lymphoma-prone phenotypes. Novel immunological insights have enabled phenotype-based classification, guiding the development of targeted therapies against B-cell pathways, cytokines, and co-stimulatory molecules with several agents (e.g., belimumab, ianalumab, telitacicept) showing promise in reducing disease activity scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Recent advances provide a framework for precision medicine in SjD, integrating molecular and imaging biomarkers into patient selection and treatment monitoring. Clinically, this could enable earlier diagnosis, individualized risk assessment, and tailored therapy. Research priorities now include validating diagnostic innovations in diverse populations, elucidating phenotype-specific mechanisms, and conducting adequately powered, biomarker-driven trials to optimize therapeutic efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001132","type":"journal-article","created":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:00:15Z","timestamp":1760270415000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Advances in the diagnosis and treatment of Sj\u00f6gren disease"],"prefix":"10.1097","volume":"38","author":[{"given":"Christos","family":"Tsironis","sequence":"first","affiliation":[{"name":"Departments of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asimina I.","family":"Karampela","sequence":"additional","affiliation":[{"name":"Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clio P.","family":"Mavragani","sequence":"additional","affiliation":[{"name":"Departments of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"R1-20251204","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41584-025-01268-z","volume":"21","author":"Ramos-Casals","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"R2-20251204","doi-asserted-by":"crossref","first-page":"E579","DOI":"10.1503\/cmaj.122037","article-title":"Sj\u00f6gren syndrome","volume":"186","author":"Mavragani","year":"2014","journal-title":"Can Med Assoc J"},{"key":"R3-20251204","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41584-023-01057-6","article-title":"Epidemiology of Sj\u00f6gren syndrome","volume":"20","author":"Beydon","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"R4-20251204","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/1744666X.2023.2234641","article-title":"Why do drug treatments fail in Sj\u00f6gren's disease? Considerations for treatment, trial design and interpretation of clinical efficacy","volume":"19","author":"Arends","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"R6-20251204","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/rheumatology\/keae152","article-title":"British Society for Rheumatology guideline on management of adult and juvenile onset Sj\u00f6gren disease","volume":"64","author":"Price","year":"2025","journal-title":"Rheumatology"},{"key":"R7-20251204","doi-asserted-by":"crossref","first-page":"e11774","DOI":"10.1002\/acr2.11774","article-title":"Contraceptives or hormone replacement therapy and associations with autoimmune conditions: exploring effects of estrogen analog supplementation","volume":"7","author":"Tskhakaia","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"R8-20251204","doi-asserted-by":"crossref","first-page":"9379","DOI":"10.1038\/s41598-025-92691-5","article-title":"Sj\u00f6gren's syndrome increased risk of attempted suicide","volume":"15","author":"Yang","year":"2025","journal-title":"Sci Rep"},{"key":"R9-20251204","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1007\/s10067-024-07132-x","article-title":"Can unstimulated whole salivary flow objectively classify salivary gland secretory function in Sj\u00f6gren's syndrome?","volume":"43","author":"Peng","year":"2024","journal-title":"Clin Rheumatol"},{"key":"R10-20251204","doi-asserted-by":"crossref","first-page":"18609","DOI":"10.1038\/s41598-025-03284-1","article-title":"Ophthalmologic and serologic predictors of positive minor salivary gland biopsy in suspected Sj\u00f6gren's disease","volume":"15","author":"Baytaro\u011flu","year":"2025","journal-title":"Sci Rep"},{"key":"R11-20251204","doi-asserted-by":"crossref","first-page":"e42054","DOI":"10.1097\/MD.0000000000042054","article-title":"Predictive value of dry eye disease signs and corneal in vivo confocal microscopy on serological activity in primary Sj\u00f6gren disease","volume":"104","author":"Wang","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"R12-20251204","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.3390\/ijms26104797","article-title":"Additive value of rheumatoid factor isotypes in Sj\u00f6gren's syndrome patients with joint complaints of different etiologies\u2014can rheumatoid factor IgA serve as an early, poor prognostic biomarker candidate?","volume":"26","author":"Aradi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R13-20251204","doi-asserted-by":"crossref","first-page":"e005386","DOI":"10.1136\/rmdopen-2024-005386","article-title":"Different rheumatoid factor binding patterns distinguish between Sj\u00f6gren's disease with or without associated RA","volume":"11","author":"Oskam","year":"2025","journal-title":"RMD Open"},{"key":"R14-20251204","doi-asserted-by":"crossref","first-page":"e005212","DOI":"10.1136\/rmdopen-2024-005212","article-title":"Isolated anti-SS-B (La) antibodies: rare occurrence and lack of diagnostic value","volume":"11","author":"Cioni","year":"2025","journal-title":"RMD Open"},{"key":"R15-20251204","doi-asserted-by":"crossref","first-page":"152026","DOI":"10.1016\/j.semarthrit.2022.152026","article-title":"Scleroderma-specific autoantibodies: should they be included in the diagnostic work-up for Sj\u00f6gren's syndrome?","volume":"55","author":"Marketos","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"R16-20251204","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1038\/s41598-024-55767-2","article-title":"Anticentromere antibody positivity is an independent variable associated with salivary gland ultrasonography score in Sj\u00f6gren's syndrome","volume":"14","author":"Shimizu","year":"2024","journal-title":"Sci Rep"},{"key":"R17-20251204","doi-asserted-by":"crossref","first-page":"14505","DOI":"10.1038\/s41598-024-65487-2","article-title":"Fluorescence-based reagent and spectrum-based optical reader for lactoferrin detection in tears: differentiating Sj\u00f6gren's syndrome from non-Sj\u00f6gren's dry eye syndrome","volume":"14","author":"Tsai","year":"2024","journal-title":"Sci Rep"},{"key":"R18-20251204","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1038\/s41598-024-59850-6","article-title":"Raman hyperspectroscopy of saliva and machine learning for Sj\u00f6gren's disease diagnostics","volume":"14","author":"Vyas","year":"2024","journal-title":"Sci Rep"},{"key":"R19-20251204","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13075-024-03459-7","article-title":"A noninvasive model for diagnosis of primary Sjogren's disease based on salivary biomarkers, serum autoantibodies, and Schirmer's test","volume":"26","author":"Zhang","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"R20-20251204","doi-asserted-by":"crossref","first-page":"e005166","DOI":"10.1136\/rmdopen-2024-005166","article-title":"Association of mitochondrial RNA expression levels in saliva and plasma with interferon signature gene expression and disease activity in patients with Sj\u00f6gren disease","volume":"11","author":"Ha","year":"2025","journal-title":"RMD Open"},{"key":"R21-20251204","doi-asserted-by":"crossref","first-page":"1524940","DOI":"10.3389\/fimmu.2025.1524940","article-title":"Identification of novel autoantibodies in Sj\u00f6gren's disease","volume":"16","author":"Engelke","year":"2025","journal-title":"Front Immunol"},{"key":"R22-20251204","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/ard-2023-224936","article-title":"Novel autoantibodies help diagnose anti-SSA antibody negative Sj\u00f6gren disease and predict abnormal labial salivary gland pathology","volume":"83","author":"Parker","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R23-20251204","doi-asserted-by":"crossref","first-page":"20007","DOI":"10.1038\/s41598-025-03698-x","article-title":"Serum growth differentiation factor 15 associates with extra-glandular manifestations and disease activity of primary Sj\u00f6gren's syndrome","volume":"15","author":"Fu","year":"2025","journal-title":"Sci Rep"},{"key":"R25-20251204","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2665-9913(23)00340-5","article-title":"Identification of distinct subgroups of Sj\u00f6gren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts","volume":"6","author":"Nguyen","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"R26-20251204","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/art.43096","article-title":"Distinct pathophysiologic pathways support stratification of Sj\u00f6gren's disease based on symptoms, clinical, and routine biological data","volume":"77","author":"Nguyen","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R27-20251204","doi-asserted-by":"crossref","DOI":"10.1002\/art.43207","article-title":"Deep immunophenotyping and clustering identifies biomarkers predictive of lymphoma in primary Sj\u00f6gren disease","author":"Marques","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R28-20251204","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1093\/rheumatology\/keaf158","article-title":"Kynurenines and neopterin are interferon-gamma-inducible biomarkers for Sj\u00f6gren's disease","volume":"64","author":"Valim","year":"2025","journal-title":"Rheumatology"},{"key":"R29-20251204","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/dmfr\/twad007","article-title":"Diagnostic accuracy of ultrasonography in relation to salivary gland biopsy in Sj\u00f6gren's syndrome: a systematic review with meta-analysis","volume":"53","author":"Martins","year":"2024","journal-title":"Dentomaxillofacial Radiol"},{"key":"R30-20251204","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s10067-025-07369-0","article-title":"Clinical value of salivary gland ultrasonography in evaluating secretory function, disease activity, and lymphoma risk factors in primary Sj\u00f6gren's syndrome","volume":"44","author":"Yang","year":"2025","journal-title":"Clin Rheumatol"},{"key":"R32-20251204","doi-asserted-by":"crossref","first-page":"103425","DOI":"10.1016\/j.autrev.2023.103425","article-title":"Is minor salivary gland biopsy still mandatory in Sjogren's syndrome? Does seronegative Sjogren's syndrome exist?","volume":"23","author":"Baldini","year":"2024","journal-title":"Autoimmun Rev"},{"key":"R33-20251204","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ard.2025.01.038","article-title":"Increasing the number of minor salivary glands from patients with Sj\u00f6gren's disease improves the diagnostic and measurement precision of the histological focus score","volume":"84","author":"Tryposkiadis","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R34-20251204","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/art.42723","article-title":"Increased diagnostic accuracy of the labial gland biopsy in primary Sj\u00f6gren syndrome when multiple histopathological features are included","volume":"76","author":"Van Ginkel","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R35-20251204","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.3390\/ijms26136463","article-title":"Minor salivary gland biopsy in the differential diagnosis of Sicca syndrome: a monocentric cohort analysis","volume":"26","author":"Fiorentini","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R36-20251204","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1007\/s10067-025-07518-5","article-title":"Artificial intelligence-based prediction of organ involvement in Sjogren's syndrome using labial gland biopsy whole-slide images","volume":"44","author":"Ren","year":"2025","journal-title":"Clin Rheumatol"},{"key":"R37-20251204","doi-asserted-by":"crossref","first-page":"103418","DOI":"10.1016\/j.jaut.2025.103418","article-title":"Evaluation of minor labial salivary gland focus score in Sj\u00f6gren's disease using deep learning: a tool for more efficient diagnosis and future tissue biomarker discovery","volume":"153","author":"Panagiotopoulos","year":"2025","journal-title":"J Autoimmun"},{"key":"R38-20251204","doi-asserted-by":"crossref","first-page":"e005884","DOI":"10.1136\/rmdopen-2025-005884","article-title":"Diagnostic value of high-frequency ultrasound assessment of the lacrimal glands for primary Sj\u00f6gren's disease","volume":"11","author":"Terslev","year":"2025","journal-title":"RMD Open"},{"key":"R39-20251204","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00330-023-10166-5","article-title":"The diagnostic performance of salivary gland ultrasound elastography in Sj\u00f6gren's syndrome and sicca symptoms: a systematic review and meta-analysis","volume":"34","author":"Dai","year":"2023","journal-title":"Eur Radiol"},{"key":"R40-20251204","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10792-024-03185-8","article-title":"Systematic review and meta-analysis of the diagnostic performance of lacrimal gland ultrasound elastography in primary Sj\u00f6gren's syndrome","volume":"44","author":"Zhang","year":"2024","journal-title":"Int Ophthalmol"},{"key":"R41-20251204","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1093\/rheumatology\/kead071","article-title":"FDG-PET\/CT discriminates between patients with and without lymphomas in primary Sj\u00f6gren's syndrome","volume":"62","author":"Van Ginkel","year":"2023","journal-title":"Rheumatology"},{"key":"R42-20251204","doi-asserted-by":"crossref","first-page":"102578","DOI":"10.1016\/j.coi.2025.102578","article-title":"Can we cure Sjogren's disease? Unmet needs and raising questions in the era of Precision medicine","volume":"95","author":"Chatzis","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"R43-20251204","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/art.23062","article-title":"Augmented interferon-alpha pathway activation in patients with Sj\u00f6gren's syndrome treated with etanercept","volume":"56","author":"Mavragani","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R44-20251204","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jama.2010.1014","article-title":"Treatment of primary Sj\u00f6gren syndrome: a systematic review","volume":"304","author":"Ramos-Casals","year":"2010","journal-title":"JAMA"},{"key":"R45-20251204","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R46-20251204","doi-asserted-by":"crossref","first-page":"102084","DOI":"10.1016\/j.berh.2025.102084","article-title":"Novel therapies in Sj\u00f6gren's disease: a systematic review of the literature","author":"Pelkas","year":"2025","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R48-20251204","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R49-20251204","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"R50-20251204","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R51-20251204","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sj\u00f6gren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"D\u00f6rner","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R52-20251204","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2024","journal-title":"Rheumatology"},{"issue":"(Suppl 1)","key":"R53-20251204","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/annrheumdis-2024-eular.LBA90","article-title":"LBA0010 Efficacy and safety of nipocalimab, an ANTI-FcRn monoclonal antibody, in primary sjogren's disease: results from a phase 2, multicenter, randomized, placebo-controlled, double-blind study (dahlias)","volume":"83","author":"Gottenberg","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R54-20251204","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"Clair","year":"2024","journal-title":"Nat Med"},{"key":"R55-20251204","doi-asserted-by":"crossref","first-page":"e163030","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren's syndrome","volume":"7","author":"Mariette","year":"1984","journal-title":"JCI Insight"},{"key":"R56-20251204","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sj\u00f6gren's syndrome: an open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"(Suppl 2)","key":"R57-20251204","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2019-eular.3098","article-title":"Op0202 effect of Rslv-132 on fatigue in patients with primary Sj\u00f6gren's syndrome \u2013 results of a phase II randomised, double-blind, placebo-controlled, proof of concept study","volume":"78","author":"Fisher","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T15:00:57Z","timestamp":1764860457000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001132","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]}}}